Jubilant Ingrevia Ltd
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.
Strengths
- +Company has been maintaining a healthy dividend payout of 36.9%
Weaknesses
- −Stock is trading at 4.54 times its book value
- −Company has a low return on equity of 10.4% over last 3 years.
- −Promoter holding has decreased over last 3 years: -6.25%
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.47% | 51.47% | 51.47% | 51.47% | 45.22%▼6.3 | 45.22% | 45.22% | 45.22% |
| FIIs | 6.55% | 7.22%▲0.7 | 6.89%▼0.3 | 7.12%▲0.2 | 6.96%▼0.2 | 5.96%▼1.0 | 6.15%▲0.2 | 6.49%▲0.3 |
| DIIs | 14.07% | 15.47%▲1.4 | 15.99%▲0.5 | 15.91%▼0.1 | 21.81%▲5.9 | 23.04%▲1.2 | 24%▲1.0 | 24.76%▲0.8 |
| Public | 27.1% | 25.09%▼2.0 | 24.9%▼0.2 | 24.76%▼0.1 | 25.3%▲0.5 | 24.94%▼0.4 | 23.8%▼1.1 | 22.53%▼1.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,003 | 917 | 1,037 | 969 | 1,005 | 995 | 972 | 973 | 1,054 | 1,018 |
| Expenses | 882 | 843 | 943 | 881 | 878 | 864 | 844 | 852 | 953 | 906 |
| Operating Profit | 121 | 74 | 94 | 88 | 128 | 131 | 128 | 121 | 101 | 112 |
| OPM % | 12% | 8% | 9% | 9% | 13% | 13% | 13% | 12% | 10% | 11% |
| Net Profit | 57 | 19 | 31 | 33 | 60 | 81 | 90 | 59 | 44 | 60 |
| EPS ₹ | 3.6 | 1.21 | 1.94 | 2.06 | 3.78 | 5.06 | 5.64 | 3.7 | 2.76 | 3.75 |
AI Insights
TTM revenue at ₹4,017Cr, up 1.9% YoY. OPM at 12%.
Borrowings at ₹824Cr. Debt-to-equity ratio: 0.33x. Healthy balance sheet.
CWIP at ₹171Cr (7% of fixed assets). Moderate ongoing capital expenditure.
DIIs: 24.76% (+18.04pp change). FIIs: 6.49% (+0.34pp change). Promoters hold 45.22%.
ROCE improving from 0% (Mar 2020) to 13% (Mar 2025). Working capital days: 18.
PE 43.5x with 12.8% ROCE. Price is 353% above book value of ₹158. Dividend yield: 0.68%.
Recent Announcements
- Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 5 May - Appeal order confirms FY17-18 GST demand of Rs 1.02 crore, equal penalty and interest; company will appeal GSTAT.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Apr - Schedule for Investor Conference Call for Jubilant Ingrevia Limited -Audited Financial Results for the quarter and year ended March 31, 2026
- Board Meeting Intimation for Intimation Of Board Meeting - May 26, 2026 28 Apr - Board meets May 26, 2026 to approve audited FY26 results and consider final dividend.
- Clarification On Price Movement In Shares Of Jubilant Ingrevia Limited 23 Apr - Jubilant Ingrevia clarified on April 23, 2026 that no material unpublished information exists.
- Clarification sought from Jubilant Ingrevia Ltd 23 Apr - Exchange has sought clarification from Jubilant Ingrevia Ltd on April 23, 2026, with reference to Movement in Volume.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse